# OnCo record nct06505837 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06505837/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06505837", "NCT06505837" ;
  schema:name "JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）"@en ;
  schema:description "A phase 3 trial of pemetrexed and toripalimab in lung cancer, run by Shanghai Junshi Bioscience Co., Ltd., active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06505837/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06505837> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/toripalimab/> ;
  onco:companies <https://onco.cc/companies/junshi/> .